275 related articles for article (PubMed ID: 22132879)
1. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.
Vossenkämper A; Lutalo PM; Spencer J
Clin Exp Immunol; 2012 Jan; 167(1):7-14. PubMed ID: 22132879
[TBL] [Abstract][Full Text] [Related]
2. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Coca A; Sanz I
Curr Opin Rheumatol; 2012 Sep; 24(5):451-6. PubMed ID: 22871954
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion in lupus and Sjögren's syndrome: an update.
Coca A; Sanz I
Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
[TBL] [Abstract][Full Text] [Related]
4. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus.
Szabó K; Papp G; Szántó A; Tarr T; Zeher M
Clin Exp Immunol; 2016 Jan; 183(1):76-89. PubMed ID: 26358223
[TBL] [Abstract][Full Text] [Related]
6. B-cell depletion and repopulation in autoimmune diseases.
Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
[TBL] [Abstract][Full Text] [Related]
7. [B cell abnormality in systemic lupus erythematosus].
Kitagori K; Kawabata D
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(6):495-502. PubMed ID: 23291484
[TBL] [Abstract][Full Text] [Related]
8. The future of B cell-targeted therapies in Sjögren's syndrome.
Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
10. Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine.
Quartuccio L; De Marchi G; Longhino S; Manfrè V; Rizzo MT; Gandolfo S; Tommasini A; De Vita S; Fox R
Front Immunol; 2021; 12():703780. PubMed ID: 34322134
[TBL] [Abstract][Full Text] [Related]
11. B-cell populations and sub-populations in Sjögren's syndrome.
Hamza N; Bos NA; Kallenberg CG
Presse Med; 2012 Sep; 41(9 Pt 2):e475-83. PubMed ID: 22841377
[TBL] [Abstract][Full Text] [Related]
12. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.
Idborg H; Zandian A; Sandberg AS; Nilsson B; Elvin K; Truedsson L; Sohrabian A; Rönnelid J; Mo J; Grosso G; Kvarnström M; Gunnarsson I; Lehtiö J; Nilsson P; Svenungsson E; Jakobsson PJ
Arthritis Res Ther; 2019 Feb; 21(1):62. PubMed ID: 30777133
[TBL] [Abstract][Full Text] [Related]
13. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
Ebo D; DeClerck LS; Bridts CH; Stevens WJ
In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494
[TBL] [Abstract][Full Text] [Related]
15. B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.
Hayakawa I; Tedder TF; Zhuang Y
Immunology; 2007 Sep; 122(1):73-9. PubMed ID: 17472721
[TBL] [Abstract][Full Text] [Related]
16. What do we know about memory B cells in primary Sjögren's syndrome?
Hansen A; Daridon C; Dörner T
Autoimmun Rev; 2010 Jul; 9(9):600-3. PubMed ID: 20452465
[TBL] [Abstract][Full Text] [Related]
17. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
18. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
[TBL] [Abstract][Full Text] [Related]
19. Primary Sjögren's syndrome and deficiency of ICA69.
Winer S; Astsaturov I; Cheung R; Tsui H; Song A; Gaedigk R; Winer D; Sampson A; McKerlie C; Bookman A; Dosch HM
Lancet; 2002 Oct; 360(9339):1063-9. PubMed ID: 12383988
[TBL] [Abstract][Full Text] [Related]
20. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]